Novel cardiovascular therapeutics have the potential to improve health outcomes, but financial toxicity from high out-of-pocket costs can limit the reach of these medications and worsen existing health disparities. Understanding the phenomenon of financial toxicity in treating cardiovascular disease is crucial to achieving health equity.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Birger, M. et al. Spending on cardiovascular disease and cardiovascular risk factors in the United States: 1996 to 2016. Circulation 144, 271–282 (2021).
Zafar, S. Y. & Abernethy, A. P. Financial toxicity, part I: a new name for a growing problem. Oncology (Williston Park) 27, 80–81, 149 (2013).
Myers, K. D. et al. Effect of access to prescribed PCSK9 inhibitors on cardiovascular outcomes. Circ. Cardiovasc. Qual. Outcomes 12, e005404 (2019).
Chiou, T. T., Tomasi, K., Taub, P. R. & Wilkinson, M. J. Inclisiran creates unique opportunities and challenges for patient access to therapy: early experience in a United States lipid clinic. J. Clin. Lipidol. 17, 73–77 (2023).
Gunn, A. H., Warraich, H. J. & Mentz, R. J. Costs of care and financial hardship among patients with heart failure. Am. Heart J. 269, 94–107 (2024).
Ali, H. R. et al. Subjective financial hardship due to medical bills among patients with heart failure in the United States: the 2014–2018 Medical Expenditure Panel Survey. J. Card. Fail. 28, 1424–1433 (2022).
Wang, S. Y. et al. Out-of-pocket annual health expenditures and financial toxicity from healthcare costs in patients with heart failure in the United States. J. Am. Heart Assoc. 10, e022164 (2021).
Luo, J. et al. Evaluation of out-of-pocket costs and treatment intensification with an SGLT2 inhibitor or GLP-1 RA in patients with type 2 diabetes and cardiovascular disease. JAMA Netw. Open 6, e2317886 (2023).
Essien, U. R. et al. Association of prescription co-payment with adherence to glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter-2 inhibitor therapies in patients with heart failure and diabetes. JAMA Netw. Open 6, e2316290 (2023).
Kazi, D. S., Wadhera, R. K. & Rome, B. N. The Inflation Reduction Act and access to high-cost cardiovascular therapies. J. Am. Med. Assoc. 330, 1619–1620 (2023).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Gunn, A.H., Pendyal, A. Novel cardiovascular therapeutics and the risk of financial toxicity. Nat Rev Cardiol 21, 349–350 (2024). https://doi.org/10.1038/s41569-024-01010-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41569-024-01010-4